Home › Onglyza (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating ...
 

Keywords :   


Onglyza (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating ...

2013-09-02 10:10:35| Biotech - Topix.net

Onglyza Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial AstraZeneca and Bristol-Myers Squibb Company today announced the full results of the SAVOR clinical trial in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular ... (more)

Tags: primary safety demonstrating achieves

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.11171
15.11 3FLYOVER
15.11 PSA8 - 1ed
15.11DMC RAVEN 18g
15.11LOVE or DEAD Blu-ray
15.11 HSGI SURE-GRIP PADDED BELT a-tacs au
15.11 BOUNTY HUNTER
15.11
More »